<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840550</url>
  </required_header>
  <id_info>
    <org_study_id>IN_APA_308</org_study_id>
    <nct_id>NCT04840550</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tegoprazan 25 mg for the Prevention of Peptic Ulcer Disease in Patients on Continuous Long-term Treatment With NSAIDs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to confirm the non-inferiority of Tegoprazan 25 mg, compared to&#xD;
      Lansoprazole 15 mg, to prevent gastroduodenal ulcers and verify the safety of tegoprazan&#xD;
      following oral administration of tegoprazan 25 mg QD or lansoprazole 15 mg QD in patients on&#xD;
      long-term treatment with NSAIDs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, active-controlled, phase 3 study. Subjects will be&#xD;
      randomly assigned to one of the two treatment groups (tegoprazan 25 mg, lansoprazole 15 mg).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with gastric and/or duodenal ulcers at Week 24</measure>
    <time_frame>week 24</time_frame>
    <description>The proportion of subjects with gastric and/or duodenal ulcers on upper GI endoscopy at Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects without NSAID-related GI symptoms at Weeks 4, 12, and 24</measure>
    <time_frame>week 4, 12, 24</time_frame>
    <description>GI symptoms are as follows; Heartburn, Regurgitation, Upper abdominal pain or discomfort</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Preventive Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Tegoprazan 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan 25mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole 15mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lansoprazole 15mg capsules will be orally administered, once a day, with NSAIDs, for up to 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole 15 mg</intervention_name>
    <description>Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.</description>
    <arm_group_label>Lansoprazole 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan 25 mg</intervention_name>
    <description>Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.</description>
    <arm_group_label>Tegoprazan 25mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥60 years of age, or ≥20 years of age with a history of gastroduodenal ulcers (gastric&#xD;
             and/or duodenal ulcers) at screening&#xD;
&#xD;
          -  Requires continued treatment with NSAIDs for ≥24 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has an active stage (A1, A2) or healing stage (H1, H2) of gastroduodenal ulcers per&#xD;
             the Sakita-Miwa classification identified by upper GI endoscopy at screening&#xD;
&#xD;
          -  Has uncontrolled severe hypertension&#xD;
&#xD;
          -  Has severe heart failure, congestive heart failure (NYHA Ⅱ to Ⅳ), ischemic heart&#xD;
             disease (unstable angina, myocardial infarction), or peripheral artery disease, or has&#xD;
             undergone coronary artery bypass graft (CABG) who is considered ineligible for&#xD;
             treatment with NSAIDs&#xD;
&#xD;
          -  Has a positive H. pylori test at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyeongmin Oh</last_name>
    <phone>82-2-6477-0272</phone>
    <email>kyeongmin.oh@inno-n.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiwon Lee</last_name>
    <phone>82-2-6477-0273</phone>
    <email>jiwon.lee@inno-n.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jae J. Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The catholic univ. of Korea Eunpyeong ST. Mari's hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JH Oh</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

